# Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer

> **NCT06223698** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Region Örebro County** · enrollment: 3832 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Anastrozole
- **DRUG:** Exemestane
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT06223698
- **Lead sponsor:** Region Örebro County
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-02
- **Primary completion:** 2032-05-02
- **Final completion:** 2035-05-02
- **Target enrollment:** 3832 (ESTIMATED)
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06223698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06223698, "Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06223698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*